At the 25th International AIDS Conference in Munich, ViiV Healthcare will unveil significant findings from their portfolio of HIV treatments and prevention approaches. The company, owned by GSK, Pfizer, and Shionogi, will present a portfolio of marketed HIV treatment and prevention options alongside next-generation pipeline assets.

One key highlight is the presentation of the head-to-head study comparing ViiV Healthcare’s oral 2-drug regimen, Dovato, against the widely prescribed oral 3-drug regimen, Biktarvy. This non-inferiority study evaluated virologically suppressed adults who could benefit from treatment optimization. The study will present 48-week findings on treatment efficacy, safety, and weight changes experienced by participants.

Additional findings on Dovato include the DYAD study, presenting 48-week results among virologically suppressed participants who either switched to Dovato or remained on Biktarvy, and the SOUND study, which followed virologically suppressed participants who switched from Biktarvy to Dovato for 96 weeks.

ViiV Healthcare will also share new data on the impact of cabotegravir long-acting for PrEP exposure during pregnancy from the HPTN 084 trial. The study focuses on maternal, pregnancy, and infant safety outcomes among participants who became pregnant during the extension of HPTN 084.

Additionally, researchers will present phase I findings from the first-in-human study of VH184, a third-generation integrase inhibitor (INSTI), showing potent activity against multiple INSTI-resistant mutations. This is the first data presentation of ViiV Healthcare’s next INSTI as part of its ultra-long-acting development strategy.

Source link: http://www.businesswire.com/news/home/20240712714679/en/ViiV-Healthcare-to-announce-data-from-largest-head-to-head-randomised-clinical-trial-for-2-drug-regimen-Dovato-against-3-drug-regimen-Biktarvy-at-AIDS-2024

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.